高剂量一氧化氮吸入作为重症COVID-19自主呼吸患者的挽救治疗
该回顾性研究评估了2020年3月18日至5月20日在马萨诸塞州总医院收治的5例COVID-19呼吸窘迫患者,在常规氧疗和/或清醒俯卧位下症状仍恶化时,接受160 ppm一氧化氮吸入30分钟、每日两次的面罩挽救治疗。3例接受多次治疗(5至9次)的患者均存活出院。吸入30分钟后最大高铁血红蛋白为2.0%(1.7-2.3%),二氧化氮低于2 ppm,平均动脉压和心率无变化,氧合和呼吸频率保持稳定。2例有炎症标志物数据的患者显示下降或停止升级。提示160 ppm一氧化氮可能是有效的辅助挽救治疗。
要点
- 适用对象为COVID-19呼吸窘迫、高急性低氧性呼吸衰竭风险、在补充氧和/或清醒俯卧位下仍症状恶化的自主呼吸患者。
- 干预方案为面罩吸入一氧化氮160 ppm,每次30分钟,每日两次,直至症状缓解、出院、插管或转为仅舒适治疗。
- 3例接受多次治疗(5至9次)的患者均存活出院;5例均至少接受一次治疗。
- 吸入30分钟后最大高铁血红蛋白为2.0%(1.7-2.3%),二氧化氮低于2 ppm,平均动脉压和心率无变化。
- 2例可获炎症标志物数据的患者显示标志物下降或升级停止。
适用人群与场景
- COVID-19呼吸窘迫、高急性低氧性呼吸衰竭风险、在补充氧和/或清醒俯卧位下仍症状恶化的自主呼吸患者。
- 场景为马萨诸塞州总医院2020年3月18日至5月20日COVID-19激增期间的住院患者。
诊断标准与关键阈值
- 启动条件为COVID-19呼吸窘迫且在高流量鼻导管和持续气道正压使用存在争议的背景下,作为挽救治疗使用。
处置流程与药物剂量
- 第一步:对COVID-19呼吸窘迫、在补充氧和/或清醒俯卧位下仍恶化的自主呼吸患者,考虑一氧化氮吸入作为挽救治疗。
- 第二步:通过面罩给予一氧化氮160 ppm,每次30分钟,每日两次。
- 第三步:持续至症状缓解、出院、插管或转为仅舒适治疗。
- 监测:吸入30分钟后最大高铁血红蛋白为2.0%(1.7-2.3%),二氧化氮低于2 ppm,平均动脉压和心率无变化。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或不能漏诊的情况及处理。
研究设计与关键结果
- 回顾性评估,单中心(马萨诸塞州总医院),5例COVID-19呼吸窘迫患者接受一氧化氮吸入挽救治疗。
- 所有患者至少接受一次治疗;3例接受多次治疗(5至9次)的患者均存活出院。
- 吸入30分钟后最大高铁血红蛋白为2.0%(1.7-2.3%),二氧化氮低于2 ppm。
- 治疗期间及之后平均动脉压和心率无变化,氧合和呼吸频率保持稳定。
- 2例有炎症标志物数据的患者显示下降或升级停止。
证据类型、等级与局限
- 证据类型:回顾性评估(单中心、样本量小(5例)、无对照组)。
- 局限:回顾性设计、单中心、样本量小、无对照,结果需前瞻性验证。
对床旁实践的改变
- 对于COVID-19呼吸窘迫、在补充氧和/或清醒俯卧位下仍恶化的自主呼吸患者,可考虑160 ppm一氧化氮吸入(30分钟/次,每日两次)作为挽救治疗。
- 治疗期间需监测高铁血红蛋白和二氧化氮,原文报告最大高铁血红蛋白2.0%(1.7-2.3%),二氧化氮低于2 ppm。
- 多疗程(5至9次)可能与存活出院相关,但样本量小,不能作为普遍推荐。
- 不适用于已插管或转为仅舒适治疗的患者(原文治疗终点包括插管或转为仅舒适治疗)。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Treatment options are limited for patients with respiratory failure due to coronavirus disease 2019. Conventional oxygen therapy and awake proning are options, but the use of high-flow nasal cannula and continuous positive airway pressure are controversial. There is an urgent need for effective rescue therapies. Our aim is to evaluate the role of inhaled nitric oxide 160 ppm as a possible rescue therapy in nonintubated coronavirus disease 2019 patients.
DESIGN: Retrospective evaluation of coronavirus disease 2019 patients in respiratory distress receiving nitric oxide gas as rescue therapy.
SETTING: Massachusetts General Hospital, between March 18, 2020, and May 20, 2020, during the local coronavirus disease 2019 surge.
PATIENTS: Coronavirus disease 2019 patients at high risk for acute hypoxemic respiratory failure with worsening symptoms despite use of supplemental oxygen and/or awake proning.
INTERVENTIONS: Patients received nitric oxide at concentrations of 160 ppm for 30 minutes twice per day via a face mask until resolution of symptoms, discharge, intubation, or the transition to comfort measures only.
MEASUREMENTS AND MAIN RESULTS: Between March 18, 2020, and May 20, 2020, five patients received nitric oxide inhalation as a rescue therapy for coronavirus disease 2019 at Massachusetts General Hospital. All received at least one dosage. The three patients that received multiple treatments (ranging from five to nine) survived and were discharged home. Maximum methemoglobin concentration after 30 minutes of breathing nitric oxide was 2.0% (1.7-2.3%). Nitrogen dioxide was below 2 ppm. No changes in mean arterial pressure or heart rate were observed during or after nitric oxide treatment. Oxygenation and the respiratory rate remained stable during and after nitric oxide treatments. For two patients, inflammatory marker data were available and demonstrate a reduction or a cessation of escalation after nitric oxide treatment.
CONCLUSIONS: Nitric oxide at 160 ppm may be an effective adjuvant rescue therapy for patients with coronavirus disease 2019.
参考来源
- Wiegand SB, Safaee Fakhr B, Carroll RW, et al. Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously Breathing Patients With Severe Coronavirus Disease 2019. Crit Care Explor. 2020. PMID: 33225304. doi:10.1097/CCE.0000000000000277
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。